Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes

Diabetologia

Volumn 54, Issue 5, 2011, Pages 1227-1241

  Veron, D ^a   Bertuccio, C A ^a   Marlier, A ^a   Reidy, K ^b   Garcia, A M ^b   Jimenez, J ^b   Velazquez, H ^a   Kashgarian, M ^a   Moeckel, G W ^a   Tufro, A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

MMP; Podocytes; Proteinuria; Semaphorin3a; Transgenic mice; Type 1 diabetes mellitus; VEGF A

Indexed keywords

CREATININE; GELATINASE A; SEMAPHORIN 3A; VASCULOTROPIN A;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE SEVERITY; GENE; GENE OVEREXPRESSION; GLOMERULUS BASEMENT MEMBRANE; INSULIN DEPENDENT DIABETES MELLITUS; MICROANEURYSM; MOUSE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; VEGF164 GENE;

ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; PODOCYTES; POLYMERASE CHAIN REACTION; SEMAPHORIN-3A; TANDEM MASS SPECTROMETRY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79954632427     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-2034-z     Document Type: Article

References (49)

1. G Wolf F Ziyadieh 2007 Cellular and molecular mechanisms of proteinuria in diabetic nephropathy Nephron Physiol 106 26 31 10.1159/000101797 (Pubitemid 46920097)
2. FC Brosius CC Khoury CL Buller S Chen 2010 Abnormalities in signaling pathways in diabetic nephropathy Expert Rev Endocrinol Metab 5 51 64 20224802
3. L Gnudi 2008 Molecular mechanisms of proteinuria in diabetes Biochem Soc Trans 36 946 949 18793166 10.1042/BST0360946 1:CAS:528:DC%2BD1cXhtlSrt7zL
4. ME Cooper D Vranes S Youssef, et al. 1999 Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes Diabetes 48 2229 2239 10535459 10.2337/diabetes.48.11.2229 1:CAS:528:DyaK1MXntVSlsb4%3D (Pubitemid 29521855)
5. AS de Vriese RG Tilton M Elger CC Stephan W Kriz NH Lameire 2001 Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes J Am Soc Nephrol 12 993 1000 11316858 (Pubitemid 32378340)
6. BF Schrijvers A Flyvberg AS de Vriese 2004 The role of vascular endothelial growth factor (VEGF) in renal pathophysiology Kidney Int 65 2003 2017 15149314 10.1111/j.1523-1755.2004.00621.x 1:CAS:528:DC%2BD2cXltFKgs7c%3D (Pubitemid 38669987)
7. T Nakagawa W Sato O Glushakova, et al. 2007 Diabetic eNOS knockout mice develop advanced diabetic nephropathy J Am Soc Nephrol 18 539 550 17202420 10.1681/ASN.2006050459 1:CAS:528:DC%2BD2sXit12ju7k%3D (Pubitemid 46193319)
8. T Nakagawa 2007 Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease Am J Physiol Renal Physiol 292 F1665 F1672 17545302 10.1152/ajprenal.00495.2006 1:CAS:528:DC%2BD2sXmvF2kur4%3D (Pubitemid 47105355)
9. Y Kanetsuna K Takahashi M Nagata, et al. 2007 Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice Am J Pathol 170 1473 1484 17456755 10.2353/ajpath.2007.060481 1:CAS:528:DC%2BD2sXlvFCns7o%3D (Pubitemid 47339294)
10. F Guan G Villegas J Teichman P Mundel A Tufro 2006 Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP Am J Physiol Renal Physiol 291 F422 F428 16597608 10.1152/ajprenal.00448.2005 1:CAS:528:DC%2BD28XoslWqtrk%3D (Pubitemid 44148132)
11. CH Ku KE White A Dei Cas, et al. 2008 Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice Diabetes 57 2824 2833 18647955 10.2337/db08-0647 1:CAS:528:DC%2BD1MXhs1Knt7Y%3D
12. D Veron K Reidy C Bertuccio, et al. 2010 Induction of podocyte VEGF-A oveexpression in adult mice causes glomerular disease Kidney Int 77 989 999 20375978 10.1038/ki.2010.64 1:CAS:528:DC%2BC3cXmtVSgtLY%3D
13. AL Kolodkin DV Levengood EG Rowe YT Tai RJ Giger DD Ginty 1997 Neuropilin is a semaphorin III receptor Cell 90 753 762 9288754 10.1016/S0092-8674(00) 80535-8 1:CAS:528:DyaK2sXlvFKmur0%3D (Pubitemid 27357966)
14. KJ Reidy G Villegas J Teichman, et al. 2009 Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development Development 136 3979 3989 19906865 10.1242/dev.037267 1:CAS:528:DC%2BC3cXislSksw%3D%3D
15. F Guan G Villegas J Teichman P Mundel A Tufro 2006 Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival Kidney Int 69 1564 1569 16541019 10.1038/sj.ki.5000313 1:CAS:528:DC%2BD28XjvF2ks78%3D
16. G Villegas A Tufro 2002 Ontogeny of semaphorins 3A and 3F and their receptors neuropilins 1 and 2 in the kidney Mech Dev 119 Suppl 1 S149 S153 14516677 10.1016/S0925-4773(03)00108-4 (Pubitemid 39658702)
17. HQ Miao S Soker L Feiner JL Alonso JA Raper M Klagsbrun 1999 Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165 J Cell Biol 146 233 242 10402473 1:CAS:528:DyaK1MXksFCjs7c%3D
18. T Bondeva C Rüster S Franke, et al. 2009 Advanced glycation end-products suppress neuropilin-1 expression in podocytes Kidney Int 75 605 616 19037249 10.1038/ki.2008.603 1:CAS:528:DC%2BD1MXisVSnsbw%3D
19. PS Yuen SR Dunn T Miyaji H Yasuda K Sharma RA Star 2004 A simplified method for HPLC determination of creatinine in mouse serum Am J Physiol Renal Physiol 286 F1116 F1119 14970000 10.1152/ajprenal.00366.2003 1:CAS:528:DC%2BD2cXkvFCqsbw%3D (Pubitemid 38656367)
20. ML Gross A Koch B Mühlbauer, et al. 2006 Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes Lab Invest 86 262 274 16402031 10.1038/labinvest.3700383 1:CAS:528:DC%2BD28XhsFSmtbw%3D (Pubitemid 43276958)
21. D Veron K Reidy A Marlier, et al. 2010 Induction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid resistant nephrotic syndrome Am J Pathol 177 2225 2233 20829436 10.2353/ajpath.2010.091146 1:CAS:528:DC%2BC3cXhsFWhu7fJ
22. KJ Livak TD Schmittgen 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 402 408 11846609 10.1006/meth.2001.1262 1:CAS:528:DC%2BD38XhtFelt7s%3D (Pubitemid 34164012)
23. K Ichinose Y Maeshima Y Yamamoto, et al. 2005 Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model Diabetes 54 2891 2903 16186390 10.2337/diabetes.54.10.2891 1:CAS:528:DC%2BD2MXhtV2rs77F (Pubitemid 41401084)
24. P Hovind L Tarnow PB Oestergaard HH Parving 2000 Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy Kidney Int 75 S56 S61 10.1046/j.1523-1755.2000.07504.x 1:CAS:528: DC%2BD3cXjtVOrsL0%3D (Pubitemid 30205441)
25. C Eisner R Faulhaber-Walter Y Wang, et al. 2010 Major contribution of tubular secretion to creatinine clearance in mice Kidney Int 77 519 526 20032962 10.1038/ki.2009.501 1:CAS:528:DC%2BC3cXisVans70%3D
26. MD Breyer E Böttinger FC Brosius 3rd AMDCC, et al. 2005 Mouse models of diabetic nephropathy J Am Soc Nephrol 16 27 45 15563560 10.1681/ASN. 2004080648 (Pubitemid 43073154)
27. E Gagliardini D Corna C Zoja, et al. 2009 Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes Am J Physiol Renal Physiol 297 F1448 F1456 19675181 10.1152/ajprenal.00340.2009 1:CAS:528:DC%2BD1MXhsValtrvE
28. S Doublier G Salvidio E Lupia, et al. 2003 Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II Diabetes 52 1023 1030 12663475 10.2337/diabetes.52.4.1023 1:CAS:528:DC%2BD3sXislOns7c%3D (Pubitemid 36384273)
29. RG Langham DJ Kelly AJ Cox, et al. 2002 Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition Diabetologia 45 1572 1576 12436341 10.1007/s00125-002-0946-y 1:CAS:528:DC%2BD38XoslOrsL4%3D (Pubitemid 35352051)
30. KM Thrailkill R Clay Bunn JL Fowlkes 2009 Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy Endocrine 35 1 10 18972226 10.1007/s12020-008-9114-6 1:CAS:528:DC%2BD1MXhvVyltrs%3D
31. JD Raffetto RA Khalil 2008 Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease Biochem Pharmacol 75 346 359 17678629 10.1016/j.bcp.2007.07.004 1:CAS:528:DC%2BD1cXhsVynsg%3D%3D (Pubitemid 350298459)
32. K Nitta K Uchida N Kimata, et al. 1999 Increased serum levels of vascular endothelial growth factor in human crescentic glomerulonephritis Clin Nephrol 52 76 82 10480217 1:CAS:528:DyaK1MXltFSlsbs%3D (Pubitemid 29387162)
33. E Bailey MJ Bottomley S Westwell, et al. 1999 Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation J Clin Pathol 52 735 738 10674029 10.1136/jcp.52.10.735 1:STN:280:DC%2BD3c7jvV2rtg%3D%3D (Pubitemid 29481332)
34. SE Maynard JY Min J Merchan, et al. 2003 Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 649 658 12618519 1:CAS:528:DC%2BD3sXhvFentbc%3D (Pubitemid 36278583)
35. V Eremina JA Jefferson J Kowalewska, et al. 2008 VEGF inhibition and renal thrombotic microangiopathy N Engl J Med 358 1129 1136 18337603 10.1056/NEJMoa0707330 1:CAS:528:DC%2BD1cXjt1ahs7o%3D (Pubitemid 351398487)
36. A Advani DJ Kelly SL Advani, et al. 2007 Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions Proc Natl Acad Sci U S A 104 14448 14453 17726104 10.1073/pnas.0703577104 1:CAS:528:DC%2BD2sXhtVGgu7fP (Pubitemid 350003281)
37. SH Sung FN Ziyadeh A Wang PE Pyagay YS Kanwar S Chen 2006 Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice J Am Soc Nephrol 17 3093 3104 16988063 10.1681/ASN.2006010064 1:CAS:528:DC%2BD28Xht1yjtbrK (Pubitemid 44707769)
38. K Shulman S Rosen K Tognazzi EJ Manseau LF Brown 1996 Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases J Am Soc Nephrol 7 661 666 8738799 1:STN:280:DyaK28zjt1yrtg%3D%3D (Pubitemid 27465997)
39. E Bortoloso D del Prete M Dalla Vestra, et al. 2004 Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes Eur J Endocrinol 150 799 807 15191350 10.1530/eje.0.1500799 1:CAS:528:DC%2BD2cXlvVKitb0%3D (Pubitemid 38961653)
40. TW Tervaert AL Mooyaart K Amann RP Society, et al. 2010 Pathologic classification of diabetic nephropathy J Am Soc Nephrol 21 556 563 20167701 10.1681/ASN.2010010010
41. FC Brosius 3rd CE Alpers EP Bottinger, et al. 2009 Animal models of diabetic complications consortium. Mouse models of diabetic nephropathy J Am Soc Nephrol 20 2503 2512 19729434 10.1681/ASN.2009070721
42. T Lenz T Haak J Malek HJ Gröne H Geiger J Gossmann 2003 Vascular endothelial growth factor in diabetic nephropathy Kidney Blood Press Res 26 338 343 14610338 10.1159/000073940 1:CAS:528:DC%2BD3sXovVajsrw%3D (Pubitemid 37465042)
43. JC Peterson S Adler JM Burkart, et al. 1995 Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study Ann Intern Med 123 754 762 7574193 1:STN:280: DyaK28%2FjtVOntw%3D%3D
44. RC Atkins EM Briganti JB Lewis, et al. 2005 Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy Am J Kidney Dis 45 281 287 15685505 10.1053/j.ajkd.2004.10.019 (Pubitemid 40431053)
45. R Tapia F Guan I Gershin J Teichman G Villegas A Tufro 2008 Semaphorin3a disrupts podocyte foot processes causing acute proteinuria Kidney Int 73 733 740 18075495 10.1038/sj.ki.5002726 1:CAS:528:DC%2BD1cXis1Wmtbg%3D (Pubitemid 351323249)
46. MS Forbes BA Thornhill MH Park RL Chevalier 2007 Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury Am J Pathol 170 87 99 17200185 10.2353/ajpath.2007.060610 1:CAS:528:DC%2BD2sXhsV2gur4%3D (Pubitemid 47339192)
47. M Arraj B Lemmer 2007 Endothelial nitric oxide is not involved in circadian rhythm generation of blood pressure: experiments in wild-type C57 and eNOS knock-out mice under light-dark and free-run conditions Chronobiol Int 24 1231 1240 18075809 10.1080/07420520701795357 1:CAS:528:DC%2BD2sXhsVagt73I (Pubitemid 350256129)
48. T Kosugi T Nakayama Q Li, et al. 2010 Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice Am J Physiol Renal Physiol 298 F609 F616 20015944 10.1152/ajprenal.00377. 2009 1:CAS:528:DC%2BC3cXjsFGntbY%3D
49. Y Bai L Wang Y Li, et al. 2006 High ambient glucose levels modulates the production of MMP-9 and alpha5(IV) collagen by cultured podocytes Cell Physiol Biochem 17 57 68 16543722 10.1159/000091464 1:CAS:528:DC%2BD28Xitl2rtbs%3D